L. Post

A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev.

B. Fox, G. Nabel, C. B. Thompson, 1994, Human gene therapy.

CD38 x ICAM1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma

O. K. Wong, Xiaocheng Chen, L. Post, 2021, Blood.

Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription

K. Harvey, T. Tang, Joseph Rosenbluh, 2023, bioRxiv.

Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma

D. Jagger, D. Parkinson, T. Tang, 2022, Brain : a journal of neurology.

Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) muta

J. Desai, A. Tolcher, D. Kwiatkowski, 2023, Cancer Research.

TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors.

C. Der, Andrew M. Waters, Jill Hallin, 2023, Cancer research.